Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD19 immunogen polypeptide and application thereof

An immunogen and cellular immunity technology, applied in the direction of immunoglobulin superfamily, specific peptides, cancer antigen components, etc., can solve the problems of specific T cell immunity difficulties, large molecular weight, etc., to promote binding, inhibit growth, and promote CD8+ The effect of the immune response

Inactive Publication Date: 2016-10-12
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, CD19 is composed of a 95KDa protein with a large molecular weight, so it is difficult to obtain high-purity CD19
In this way, it will not only bring difficulties to the specific T cell immunity in the later stage, but also lead to the patient's autoimmunity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD19 immunogen polypeptide and application thereof
  • CD19 immunogen polypeptide and application thereof
  • CD19 immunogen polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Proliferation of T lymphocytes: Spleen of mice was aseptically taken, washed 3 times with 1640 medium, ground with a 5ml syringe core, filtered with a 200-mesh screen to make a single-cell suspension, centrifuged (1000r / min, 5min), discarded Qing, Tris-NH 4 CL cracked red blood cells, put them in an ice-water bath for 3-5min, centrifuged (1000r / min, 5min), discarded the supernatant, and washed the cells twice with sterile cold PBS. Add RPMI 1640 culture fluid (5ml) of 10% calf serum to suspend the cells at last, count the cells, and adjust the cell concentration to be 5×10 6 cells / ml and cultured in 96-well culture plates.

[0016] The experiment set up a blank control group, a model group (concanavalin A, purchased from sigma company), and groups of different doses of polypeptides (3, 6, 12 mg / ml). After adding 100 μl / well of spleen lymphocyte suspension to each group, 100 μl of 1640 culture medium was added to the blank control group, ConA (final concentration was 5...

Embodiment 2

[0022] Determination of immunogenicity of CD19 immunogenic polypeptides: the effect of immunogenic polypeptides on CD8+ T cells was determined by flow cytometry. C57BL / 6 mice aged 6-8w were randomly divided into 4 groups with 10 mice in each group. (1) blank group; (2) low-dose immunogenic polypeptide group; (3) medium-dose immunogenic polypeptide group; (4) high-dose polypeptide group. On the 0th, 7th, and 14th day of the experiment, immunization was carried out respectively. The scheme is: add the same volume of solvent to the blank group, set three doses of polypeptide in the experimental group: 1, 2, and 4 mg / Kg, and inject multiple points near the lymph nodes on the back of the mice. After 30 days, 0.8 ml of blood was taken from the eyeball, anticoagulated with heparin, and the blood cell layer was collected after centrifugation, and the red blood cells were cracked with red blood cell lysate, and the cracked red blood cells were washed away, and then fluorescently label...

Embodiment 3

[0028] Use the competitive receptor-ligand affinity method to test the binding ability of peptides to MHC:

[0029] The ability of the polypeptide to bind to each type of HLA was judged by the competitive receptor-ligand affinity method. Add 125I-labeled polypeptides with a fixed concentration of 50 μmol / L and polypeptides with different concentrations (1-50 μmol / L) to the reaction system (phosphate buffer and MHC, the MHC kit was purchased from Shanghai Fanke Biotechnology Co., Ltd. , there are HLA-A1, A2, A3, A11 and A24 in the kit), and two complexes are formed in the reaction system, that is, the polypeptide MHC complex to be tested and the 125I-labeled polypeptide complex. The polypeptide to be tested competes with the 125I-labeled polypeptide for binding to MHC. Use ultrafiltration (product model Microcon 30, Amicon company) to separate free polypeptide and polypeptide MHC complex, then measure the 125I radioactivity of the polypeptide MHC complex, and compare this radi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CD19 immunogen polypeptide, belongs to the field of anticancer vaccines, and particularly relates to an optimized polypeptide of CD19 immunogen used as an anticancer vaccine. The polypeptide can improve T cell immunologic response. The polypeptide has a brand new amino acid sequence and can be applied to preparation of tumor drugs, especially drugs for improving T cell immunologic response for tumor immunology cells, as well as drugs for CAR-T cell immunotherapy. The polypeptide has the advantages that the new sequence is adopted, the polypeptide can be applied to immunogen in the tumor immunology cell technology to promote T cell and CD8+ l immunologic response, to be effectively and specifically combined with MHC on the surfaces of T cells, to promote combination of T cells and tumor cells, and to inhibit the growth of tumor in tumor-bearing mice, and the polypeptide can be applied to CAR-T cell immunotherapy and the like as a target molecule of cell therapy.

Description

technical field [0001] The present invention relates to the field of anticancer vaccines. Specifically, the present invention relates to optimized polypeptides for use as CD19 immunogens in anticancer vaccines to enhance T cell immune responses. Background technique [0002] B-cell lymphoma is a solid tumor of B cells that usually occurs in children and adults. It is a type of cancer that attacks the B cells of the immune system. Includes Hodgkin's lymphoma and non-Hodgkin's lymphoma. There are many types of Hodgkin's lymphoma, classical Hodgkin's lymphoma and nodular lymphocyte-predominant Hodgkin's lymphoma, which are now considered to be tumors originating from B cells. Diffuse large B-cell lymphoma, follicular lymphoma, mucosa-associated lymphoid tissue lymphoma (MALT), small lymphocytic lymphoma / chronic lymphocytic leukemia, mantle cell lymphoma (MCL) 5 types of B-cell non-Hodgkin Lymphoma is the most common, accounting for 3 / 4 of non-Hodgkin's lymphomas. The progno...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/705A61K39/00A61P35/00
CPCA61K39/0011A61K2039/57C07K14/70503
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com